Objectives: To promote generic drug use, Japanese government had been implementing aggressive financial incentives to hospitals, physicians and pharmacies for over a decade. This study describes the recent generic drug policies in Japan and the future directions. Methods: Information on generic drug uptake and policies were retrieved from the websites of Ministry of Health, Labour and Welfare (MHLW) and Japan Generic Medicines Association as well as grey literature. Medical and pharmacy fees were obtained from MHLW. Policy impacts and future directions were analysed by reviewing literature and discussion meeting minutes at Chuikyo (Japanese Central Social Insurance Medical Council). Results: :. On June 2017, the government officially set the target rate of generic drug use at 80% by September 2020 and introduced aggressive financial incentives in the National Health Insurance scheme to increase its uptake. The current pro-generics policies include additional fees reimbursed to physicians for prescribing generics, premiums to hospitals and clinics that achieve high rate of generic use, premiums (or disincentives) to pharmacies that achieve (or penalize) high (or low) dispense rate of generics. These policies helped to increase the uptake of generic drugs consistently, from 60% in 2015 to 74% in 2018. Based on current discussions at Chuikyo, future policies are expected in the following areas: incentives to increase biosimilar use, promotion to replace long-listed drugs with generics, and customization of drug formularies to local healthcare needs. Conclusions: Japanese government promotes generic drugs through strong financial incentives to hospitals, physicians, and pharmacies. As a result, the use of generic drugs has increased consistently over the years and is expected to grow even further. Given the trend, there is a growing need for pharmaceutical companies to differentiate their products from generic drugs.
based on the epidemiological transition level (ETL) of states/UTs. ETL is defined as the ratio of DALYs due to communicable, maternal, neonatal and nutritional diseases versus NCDs and injuries. Results: The total NCDs-related deaths across all the states/UT was reported to be 348/100,000 (251-446/100,000) in 1990 and 440/100,000 (265-704/ 100,000) in 2017. The NCDs-related death rate was high in .40 years age group. Similarly, the NCDs-related DALYs was reported to be 17,862/100,000 (14,534-21,982/ 100,000) in 1990 and 19,051/100,000 (14,219-23,818/100,000) in 2017. An increase in the overall NCDs' burden was observed across states from 1990-2017, irrespective of their ETL status; however, it was higher in states with high ETL status. In 2017, the highest burden of NCDs was reported in Kerala, followed by Karnataka, and Tamil Nadu. Conclusions: NCDs pose major public health issue with varied burden across different states in India. With increasing NCDs' burden, the most affected states/UTs need more effective health policy intervention in India.
Objectives: To promote generic drug use, Japanese government had been implementing aggressive financial incentives to hospitals, physicians and pharmacies for over a decade. This study describes the recent generic drug policies in Japan and the future directions. Methods: Information on generic drug uptake and policies were retrieved from the websites of Ministry of Health, Labour and Welfare (MHLW) and Japan Generic Medicines Association as well as grey literature. Medical and pharmacy fees were obtained from MHLW. Policy impacts and future directions were analysed by reviewing literature and discussion meeting minutes at Chuikyo (Japanese Central Social Insurance Medical Council). Results: :. On June 2017, the government officially set the target rate of generic drug use at 80% by September 2020 and introduced aggressive financial incentives in the National Health Insurance scheme to increase its uptake. The current pro-generics policies include additional fees reimbursed to physicians for prescribing generics, premiums to hospitals and clinics that achieve high rate of generic use, premiums (or disincentives) to pharmacies that achieve (or penalize) high (or low) dispense rate of generics. These policies helped to increase the uptake of generic drugs consistently, from 60% in 2015 to 74% in 2018. Based on current discussions at Chuikyo, future policies are expected in the following areas: incentives to increase biosimilar use, promotion to replace long-listed drugs with generics, and customization of drug formularies to local healthcare needs. Conclusions: Japanese government promotes generic drugs through strong financial incentives to hospitals, physicians, and pharmacies. As a result, the use of generic drugs has increased consistently over the years and is expected to grow even further. Given the trend, there is a growing need for pharmaceutical companies to differentiate their products from generic drugs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.